분자 품질 관리 시장 규모 : 제품 유형별, 분석물 유형별, 용도별, 최종사용자별, 지역별, 범위 및 예측

Molecular Quality Controls Market Size And Forecast

Molecular Quality Controls Market size was valued at USD 204.18 Million in 2023 and is projected to reach USD 339.19 Million by 2031, growing at a CAGR of 6.55% from 2024 to 2031. Molecular quality controls comprise standards and processes used to verify the reliability and correctness of molecular biology techniques like polymerase chain reaction (PCR) and DNA sequencing. These controls include the use of known, preset samples with certain genetic traits that serve as benchmarks for validating the performance of laboratory equipment, reagents, and overall assay conditions. The primary objective is to uncover any irregularities or flaws in the molecular testing process, ensuring the accuracy and reproducibility of the results.

Furthermore, they play an important role in medical diagnostics to provide accurate patient diagnoses, in forensics to maintain DNA profiling integrity for the criminal justice system, and in research, labs to validate studies and contribute to scientific discoveries across multiple disciplines.

Molecular Quality Controls Market Dynamics

The key market dynamics that are shaping the Molecular Quality Controls Market include:

Key Market Drivers

Rising Demand for Accurate Diagnostics:

There is an increasing demand for accurate diagnostics and customized medicines for early diagnosis of offer on-time treatment. As a result, molecular tests play an important role in these domains, and implementing quality controls increases the dependability of test results, instilling greater confidence in the accuracy of diagnoses and treatment decisions.

Increasing Prevalence of Chronic Diseases:

Another motivating aspect is the growing prevalence of chronic diseases like cancer, diabetes, and infectious disorders. As the burden of these illnesses increases, so does the demand for molecular diagnostics, necessitating the implementation of comprehensive quality controls to ensure diagnostic test accuracy and reliability.

Advancements in Molecular Technologies:

Advances in molecular technologies, particularly next-generation sequencing (NGS) and digital PCR, help to drive industry expansion. These technological developments necessitate the establishment of customized quality controls adapted to their specific needs, ensuring the accuracy of tests performed using these advanced technologies.

Key Challenges:

Limited Awareness and Adoption:

Limited knowledge and adoption of robust quality controls provide a significant challenge. While there is a growing interest in advanced diagnostics, knowledge of the need and advantages of tight quality controls may not be universal, particularly in resource-constrained settings. This lack of awareness can lead to the underutilization of controls, compromising the accuracy and dependability of test results.

Stringent Regulations and Complex Implementation:

The application of strict rules by regulatory agencies like the FDA and EMA is a two-edged sword. While these rules are necessary to ensure the accuracy and reliability of molecular diagnostics, they also add to the costs and complexity for both manufacturers and end users. Smaller laboratories with limited resources may find compliance more difficult, limiting their capacity to properly follow these rules.

Fragmented Market:

The wide range of control types supplied by many manufacturers makes it difficult for consumers to compare and select the best controls for their unique requirements. The lack of common control materials and reference values across platforms and assays hampers quality control procedures and prevents smooth integration into multiple diagnostic processes.

Key Trends:

Growing Adoption in Point-of-Care Settings:

Another significant development is the increased use of point-of-care (POC) diagnostics. As molecular testing becomes more accessible to patients, there is a demand for portable and user-friendly quality control systems designed for decentralized settings. This is consistent with the general trend of personalized and tailored controls, indicating a shift toward adapting control solutions to specific laboratory needs and tests. As a result, the increased use of point-of-care (POC) diagnostics is a significant development in the molecular quality market.

Focus on Automation and Efficiency:

The emphasis on automation and efficiency is an ongoing trend, with laboratories increasingly implementing automated technology to streamline procedures and improve overall efficiency. This emphasis on automation extends to quality control, with manufacturers implementing automated control systems to eliminate human error and enhance data consistency, ultimately increasing the reliability of molecular testing.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Molecular Quality Controls Market Regional Analysis

Here is a more detailed regional analysis of the Molecular Quality Controls Market:

North America:

North America is estimated to dominate the Molecular Quality Controls Market during the forecast period. North America's dominant position in the Molecular Quality Controls Market is driven by the presence of well-established healthcare infrastructure and market players who are focusing on developing products and conducting research and development activities in compliance with, tight regulatory frameworks.

The region has a solid and advanced healthcare system, along with modern laboratories and diagnostic technologies. This foundation creates a climate suitable to the widespread use of molecular quality standards, which ensure diagnostic test reliability and correctness.

North America follows severe regulatory regulations, as shown by the Food and Drug Administration (FDA). These regulations promote the implementation of quality control solutions, encouraging a culture of standardized and high-quality molecular diagnostics. The commitment to regulatory compliance improves the legitimacy and dependability of diagnostic results, which contributes to the region's leading market position.

Furthermore, the presence of prominent market players like Abbott Laboratories and Roche Diagnostics in North America has a significant impact on market dynamics. These industry players contribute to the region's technological developments and innovation, paving the way for the worldwide molecular quality control market.

Europe:

Growing awareness regarding the benefits of integration of automation and importance of quality control is encouraging the strong healthcare systems to adopt molecular quality controls complying with the current stringent regulations in the region.

The presence of robust healthcare systems with modern diagnostic capabilities is anticipated to create an ideal environment for the adoption of molecular quality controls.

A tight regulatory framework, ensures a high level of quality assurance in laboratory testing methods. As European governments prioritize patient safety and precise diagnosis, the need for dependable molecular quality standards remains high.

Furthermore, automation and improved quality control technologies have become increasingly popular in Europe. Automation not only increases efficiency but also reduces the chance of human error, which aligns with the region's commitment to maintaining high molecular diagnostic standards. A confluence of all these factors enables Europe hold second dominant position in the Molecular Quality Controls Market.

Asia Pacific:

Asia Pacific is estimated to grow at the highest CAGR in the molecular quality control market during the forecast period owing to booming healthcare infrastructure tackle the increasing incidences of chronic diseases among all age groups, especially growing ageing population. In addition to this, the support and funding provided by government and the multinational and regional quality control manufacturers play a crucial role in bolstering the expansion of the current market.

The region's healthcare infrastructure has grown significantly, with greater investment in sophisticated medical facilities and diagnostic capabilities. This expansion is critical for the adoption and application of new molecular diagnostics technologies, generating the need for quality controls.

Rising awareness of chronic diseases, as well as an increased emphasis on reliable diagnostics, drive the region's demand for molecular quality controls. As populations become more health-conscious, the demand for dependable and precise diagnostic instruments grows, boosting the need for quality controls.

Furthermore, the presence of both international and regional quality control producers in the Asia Pacific area improves accessibility and availability, leading to the growth of the Molecular Quality Controls Market.

Molecular Quality Controls Market: Segmentation Analysis

The Molecular Quality Controls Market is segmented based on Product, Analyte Type, Application, End User, And Geography.

Molecular Quality Controls Market, By Product

• Independent Controls
• Instrument- Specific Controls
• Polymerase Chain Reaction (PCR)
• DNA Sequencing & NGS
• Other Technologies

Based on Product, the market is segmented into Independent Controls and Instrument-Specific Controls. The independent controls segment is estimated to dominate the Molecular Quality Controls Market during the forecast period. The independent controls product segment dominates the Molecular Quality Controls Market due to its adaptability and broad applicability. Independent controls allow laboratories to evaluate and validate a variety of molecular biology procedures, such as PCR, DNA sequencing, and nucleic acid amplification. These controls take the form of well-characterized samples with known genetic traits, allowing labs to properly monitor and troubleshoot their testing processes. As a result, the dominance of the independent controls product market emphasizes its vital role in maintaining the correctness and reliability of molecular diagnostic and research results.

Molecular Quality Controls Market, By Analyte Type

• Single-Analyte Controls
• Multi-Analyte Controls

Based on Analyte Type, the market is segmented into Single-Analyte Controls and Multi-Analyte Controls. The single-analyte controls segment is estimated to dominate the market over the forecast period. Single analyte controls dominate the analyte-type segment of the Molecular Quality Controls Market due to their focus and specialization. Single analyte controls are used to assess the performance of molecular assays that target individual analytes, such as single genes or biomarkers. This precision is especially useful for assuring the quality and dependability of diagnostic procedures and research experiments targeting specific genetic markers. Therefore, the prevalence of single analyte controls emphasizes their significance in ensuring the quality and reliability of molecular testing techniques.

Molecular Quality Controls Market, By Application

• Infectious Disease Diagnostics
• Oncology Testing
• Genetic Testing
• Others

Based on Application, the market is segmented into Infectious Disease Diagnostics, Oncology Testing, Genetic Testing, and Others. Infectious disease diagnostics application is estimated to hold the majority share in the forecast period in the Molecular Quality Controls Market owing to critical role of accurate and reliable testing in managing infectious diseases. Molecular quality controls play an important role in guaranteeing the accuracy of diagnostic assays used to detect infectious agents such as bacteria, viruses, and fungus. Strong quality controls are especially important in infectious disease diagnostics since false-positive or false-negative results can have an influence on patient treatment, public health actions, and the overall success of disease management measures. Thus, the infectious disease diagnostics segment has become a focus point for the application of molecular quality standards, driving its dominance in the market.

Molecular Quality Controls Market, By End User

• Diagnostic Laboratories
• Hospitals
• IVD Manufacturers & Contract Research Organizations
• Academic & Research Institutes
• Other End Users

Based on End User, the market is segmented into Diagnostic Laboratories, Hospitals, IVD Manufacturers & Contract Research Organizations, Academic & Research Institutes and Other End Users. Diagnostic Laboratories is estimated to hold the majority share in the forecast period in the Molecular Quality Controls Market. The diagnostic laboratories end user segment dominates the Molecular Quality Controls Market because of its vital function in delivering accurate and trustworthy diagnostic results. Diagnostic laboratories lead the way in medical testing, using molecular tools like PCR and DNA sequencing to diagnose diseases and profile patients. The dominance of the diagnostic laboratories end user segment highlights the critical role of molecular quality controls in maintaining diagnostic accuracy standards and, as a result, the overall efficacy of healthcare systems.

Key Players

• The "Molecular Quality Controls Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientific, Qiagen, Beckman Coulter, Siemens Healthineers, Bio-Rad Laboratories, Agilent Technologies, Danaher Corporation, Eurofins Scientific, Luminex Corporation, Promega Corporation, Myriad Genetics, Oxford Nanopore Technologies, Illumina, Inc., Invitae Corporation, Covance Laboratories, SeraCare Life Sciences, ACIES Biomedical, and ZeptoMetrix.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• In January 2024, Abbott announced a collaboration agreement with Personalis, Inc. to develop and market liquid biopsy controls for next-generation sequencing (NGS) experiments. This collaboration aims to improve the accuracy and reliability of liquid biopsy tests for cancer identification and monitoring.
• In January 2024, Roche Diagnostics introduced its new AmpliRun Control Set, which provides a comprehensive solution for quality control in qPCR experiments. This collection comprises controls for a variety of target genes, allowing laboratories to validate analytical performance and assure consistent results.
• In January 2024, Qiagen announced the availability of new QuantiTect viral load controls for SARS-CoV-2, hepatitis B virus (HBV), and cytomegalovirus. These controls address the increased need for precise monitoring of viral infections in clinical settings.
• In December 2023, The FDA authorized Luminex Corporation's xMAP Control Pak for Human Cytokine/Chemokine Panel. This clearance enables clinical laboratories to use these controls to conduct standardized quality assessments in immunoassay applications.
• In December 2023, Eurofins Scientific, a major provider of food, environmental, and pharmaceutical testing services, announced the purchase of Celsis Limited, which specializes in quick microbiological testing solutions. This acquisition solidifies Eurofins' leadership in the molecular quality control market for the food and beverage industry.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL MOLECULAR QUALITY CONTROLS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL MOLECULAR QUALITY CONTROLS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Instrument-Specific Controls
• 5.3 Independent Controls

6 GLOBAL MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE

• 6.1 Overview
• 6.2 Single-Analyte Controls
• 6.3 Multi-Analyte Controls

7 GLOBAL MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION

• 7.1 Overview
• 7.2 Infectious Disease Diagnostics
• 7.3 Oncology Testing
• 7.4 Genetic Testing
• 7.5 Others

8 GLOBAL MOLECULAR QUALITY CONTROLS MARKET, BY END USER

• 8.1 Overview
• 8.2 Diagnostic Laboratories
• 8.3 Hospitals
• 8.4 IVD Manufacturers & Contract Research Organizations
• 8.5 Academic & Research Institutes
• 8.6 Other End Users

9 GLOBAL MOLECULAR QUALITY CONTROLS MARKET, BY GEOGRAPHY

• 9.1 Overview
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 U.K.
  • 9.3.3 France
  • 9.3.4 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Rest of Asia Pacific
• 9.5 Rest of the World
  • 9.5.1 Latin America
  • 9.5.2 Middle East & Africa

10 GLOBAL MOLECULAR QUALITY CONTROLS MARKET COMPETITIVE LANDSCAPE

• 10.1 Overview
• 10.2 Company Market Ranking
• 10.3 Vendor Landscape
• 10.4 Key Development Strategies

11 COMPANY PROFILES

• 11.1 Abbott Laboratories
  • 11.1.1 Overview
  • 11.1.2 Financial Performance
  • 11.1.3 Product Outlook
  • 11.1.4 Key Developments
• 11.2 Roche Diagnostics
  • 11.2.1 Overview
  • 11.2.2 Financial Performance
  • 11.2.3 Product Outlook
  • 11.2.4 Key Developments
• 11.3 Thermo Fisher Scientific
  • 11.3.1 Overview
  • 11.3.2 Financial Performance
  • 11.3.3 Product Outlook
  • 11.3.4 Key Developments
• 11.4 Qiagen
  • 11.4.1 Overview
  • 11.4.2 Financial Performance
  • 11.4.3 Product Outlook
  • 11.4.4 Key Developments
• 11.5 Beckman Coulter
  • 11.5.1 Overview
  • 11.5.2 Financial Performance
  • 11.5.3 Product Outlook
  • 11.5.4 Key Developments
• 11.6 Siemens Healthineers
  • 11.6.1 Overview
  • 11.6.2 Financial Performance
  • 11.6.3 Product Outlook
  • 11.6.4 Key Developments
• 11.7 Bio-Rad Laboratories
  • 11.7.1 Overview
  • 11.7.2 Financial Performance
  • 11.7.3 Product Outlook
  • 11.7.4 Key Developments
• 11.8 Agilent Technologies
  • 11.8.1 Overview
  • 11.8.2 Financial Performance
  • 11.8.3 Product Outlook
  • 11.8.4 Key Developments
  • 11.9 Danaher Corporation
    • 11.9.1 Overview
    • 11.9.2 Financial Performance
    • 11.9.3 Product Outlook
    • 11.9.4 Key Developments
  • 11.10 Eurofins Scientific
    • 11.10.1 Overview
    • 11.10.2 Financial Performance
    • 11.10.3 Product Outlook
    • 11.10.4 Key Developments

12 KEY DEVELOPMENTS

• 12.1 Product Launches/Developments
• 12.2 Mergers and Acquisitions
• 12.3 Business Expansions
• 12.4 Partnerships and Collaborations

13 APPENDIX

• 13.1 Related Research